In a recent statement by Regeneron, they stated preclinical studies showed REGN-COV2 reduced the amount of virus and the time to alleviate symptoms in non-hospitalized patients with COVID-19
REGN-COV2 is the experimental medication which has recently garnered attention after it was administered to President Trump as part of his treatment for COVID-19. Regeneron is the biotech company that developed the antibody cocktail which has not yet been approved by the U.S. Food and Drug Administration.
Dr. Faisal Alfonso Fakih – a doctor based in central Florida, and researcher for Regeneron – says the medicine, referred to as REGN-COV2, contains two monoclonal antibodies and is not new.
“They actually used it in Ebola as well as MERS. So, they decided to test it against COVID-19,” Dr. Fakih said.